CNCT19 cell therapy for relapsed or resistant non-Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to sign the informed consent form
- You are 18 to 75 years old, and you have a specific CD19-positive non-Hodgkin lymphoma type
- Your lymphoma must have come back or not respond after at least 2nd-line treatment, or after a stem cell transplant (ASCT)
- You must have measurable lymphoma spots on scans that are large enough to track
- Your blood counts, organ function, and breathing/lung status must be adequate for treatment and apheresis
- You must be willing/able to do apheresis, and if you can become pregnant (or have a partner who can), use effective birth control during the study and for 1 year after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
This Phase 2 study tests an infusion of modified immune cells (CNCT19) in people with acute lymphoblastic leukemia (ALL) that has come back or did not respond to treatment. It may help by targeting leukemia cells that have a specific marker called CD19.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests a new cell therapy called RC19D2 for people with diffuse large B-cell lymphoma that has not responded to standard treatments. The therapy uses your own immune cells that are modified to target and kill cancer cells.
This trial tests whether IM19 can safely and effectively treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It is for adults with certain lymphoma markers and good overall functioning.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Hear when a new Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.